Introduction {#S0001}
============

Bladder cancer is the fourth most common cancer in male and it develops when abnormal cells grow in an uncontrolled way.[@CIT0001] Patients are widely categorized as non-muscle-invasive or muscle-invasive bladder tumor.[@CIT0002] Common treatment options are recommended, including surgery, chemotherapy, or combined with radiation therapy, but patients often end up with a relatively poor prognosis.[@CIT0003] Moreover, non-muscle-invasive bladder tumor constitutes the majority of patients, more often than not, which incurs a high cost and inconvenience due to frequent recurrence.[@CIT0004] Therefore, exploring more prognostic biomarkers that participate in the bladder tumor cell growth, migration, and invasion are necessary for the improvement of the patients' prognosis and life quality.

Long noncoding RNAs (lncRNAs) are a kind of noncoding RNA with more than transcripts \>200 nt in length.[@CIT0005] Ample evidence has indicated their molecular roles in tumor cell growth, metastasis, invasion, and apoptosis.[@CIT0006] For example, *TUG1* is involved in cell growth of small cell lung cancer;[@CIT0007] knockdown of *GHET1* inhibits cell proliferation and invasion of colorectal cancer;[@CIT0008] upregulated *FGF13-AS1* in breast cancer promotes invasion and metastasis.[@CIT0009] These studies contribute to a better understanding of the importance of dysregulated lncRNAs in various tumors. Many functions of lncRNAs in tumor biology have been discovered and investigated, but the molecular mechanisms of most lncRNAs in bladder tumors remain largely unknown.

In our study, lncRNA *ADAMTS9-AS2* has drawn our attention due to recent literature reports. *ADAMTS9-AS2* is known to be the antisense transcript of *ADAMTS9*[@CIT0010],[@CIT0012] and has been identified as a tumor suppressor gene if mutated.[@CIT0013],[@CIT0014] Thus, to get in-depth knowledge of *ADAMTS9-AS2*, extensive researches have been reported regarding its diverse roles in tumors including clear cell renal cell carcinoma,[@CIT0015] esophageal cancer,[@CIT0016] and ovarian cancer.[@CIT0017] Besides, accumulating researches find that *PI3K/AKT* is partially accountable for tumorigenesis and metastasis in bladder cancer.[@CIT0018],[@CIT0020] It is well-known that many lncRNAs display abnormal expression in parallel with phosphorylated *AKT1* (p-AKT1) activation of *PI3K/AKT* pathway.[@CIT0021],[@CIT0027] Therefore, we proposed a hypothesis that *ADAMTS9-AS2* cooperated with *ADAMTS9* and may participate in the bladder tumor progression by regulating the *PI3K/AKT* signal pathway.

In our study, we concentrated on the potential roles of *ADAMTS9-AS2* by investigating its influence on proliferation, migration, and invasion, which may contribute to the further understanding of bladder tumor and offer new insights for its clinical application in patients.

Materials and Methods {#S0002}
=====================

Cell Culture and Treatment {#S0002-S2001}
--------------------------

We purchased five bladder tumor cell lines (UC3, 5637, J82, T24, and EJ) and one normal cell line SV-HUC-1 from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (Thermo Fisher Scientific), with a mixture of 100 U/mL of penicillin/streptomycin. Cells were cultivated at 37°C in a humidified atmosphere containing 5% CO~2~ in air.

Quantitative PCR (q-PCR) Assays {#S0002-S2002}
-------------------------------

*ADAMTS9-AS2* and *ADAMTS9* expression were detected by q-PCR. Total RNA was first extracted from treated cells using the TRIzol reagent (Thermo Fisher Scientific) based on the manufacturer's instructions. One microgram of the total RNA was purified and used as the template for cDNA synthesis using a PrimeScript RT Reagent Kit with cDNA Eraser (Takara Biotech, Dalian, China). q-PCR was conducted using SYBR Premix Ex Taq (Takara Biotech, Dalian, China) on an ABI 7900 system (Thermo Fisher Scientific). The *GAPDH* was used as an internal control in comparisons of gene expression. Analysis of relative gene expression data was performed using 2^−ΔΔCt^. The PCR primers are shown as below: *ADAMTS9-AS2*, forward 5ʹ-AAGAAACCCTGATGTCTGGCTGAA-3ʹ and reverse 5ʹ-GTGTTACTTGAGGAGAAAGCGAAA-3ʹ; *ADAMTS9*, forward: 5ʹ-TGGGTTTTCCAGTTTTCAG-3ʹ and reverse 5ʹ-GTTGATGCTAAAACGACCC-3ʹ; *GAPDH*, forward 5ʹ- ACGGATTTGGTCGTATTGGGCG-3ʹ and reverse 5ʹ-GCTCCTGGAAGATGGTGATGGG-3ʹ.

Plasmid Construction and Cell Transfection {#S0002-S2003}
------------------------------------------

The pcDNA3.1 vector was purchased from Invitrogen (Thermo Fisher Scientific) and small interfering RNAs (siRNAs) were obtained from Ribobio (Guangzhou, China). pcDNA 3.1-*ADAMTS9-AS2* (pcDNA 3.1-AS2) was constructed by cloning the fragment of *ADAMTS9-AS2* into a pcDNA3.1 vector at the BamHI-EcoRI sites. *si-ADAMTS9-AS2-1* and *si-ADAMTS9-AS2-2* (si-AS2-1 and si-AS2-2) and the negative control siRNA (si-NC) were provided by Ribobio (Guangzhou, China). Cells were plated to the 12-well plates at a density of 2×10^3^ cells per well and cultured at least 24 h before transfection. Cells were transfected with pcDNA3.1 or pcDNA3.1-AS2, and si-NC, si-AS2-1 or si-AS2-2 by using Lipofectamine^TM^ 2000 (Thermo Fisher Scientific) following the manufacturer's instructions. Cells were incubated for 24 h and then collected for further assays after transfection. The target sequences were listed as follows: pcDNA3.1-AS2, forward 5ʹ-GGGGTACCAAACTTGACGTACACACG-3ʹ and reverse 5ʹ-AGCCGGAATTCTTTTCTGTTTTTATAATGTAC-3ʹ; si-AS2-1 5ʹ-GCATGACGCAACTTTGCTA-3ʹ (sense), si-AS2-2 5ʹ-CCTGTCTACAGGCTGATAT-3ʹ (sense).

Cell Proliferation and Clonogenic Assays {#S0002-S2004}
----------------------------------------

The CCK8 assays (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) and clonogenic assays were conducted to evaluate cell proliferation ability. As for the CCK8 assays, cells were cultured at a density of 4×10^4^ cells/well in 96-well culture plates for 18 h prior to transfection. Given the transfection efficiency of si-AS2-2 was higher than si-AS2-1, si-AS2-2 was selected in the experiments below. Cells were transfected with pcDNA 3.1 or pcDNA 3.1-AS2, and si-NC or si-AS2-2. Cells were treated with 10 mL/well of CCK8 solution during the last four hours of culture. The OD value was plotted using the 450 nm absorbance by Multiskan FC (Thermo Fisher Scientific) at each time point. In terms of clonogenic assays, in brief, cells at a density of 500 cells/well were cultured in six-well plates and cultured for two weeks under 37°C containing 5% CO~2~. The colonies were fixed with 4% paraformaldehyde for 10 min, stained with 0.1% crystal violet for 15 min and washed twice with PBS. The number of clones of each well were calculated with ImageJ software (National Institutes of Health, Bethesda, Maryland, USA). The clone formation rate of each well was counted. All experiments were performed in triplicate.

Cell Migration Assays {#S0002-S2005}
---------------------

The scratch wound healing assay was applied to observe cell migration ability. Cells were cultured at a density of 1×10^6^ cells/well in six-well culture plates for 18 h. Uniform wounds were generated prior to transfection (pcDNA 3.1 or pcDNA 3.1-AS2; si-NC or si-AS2-2). Microphotographs were taken at 0, 24, 48, and 72 h after transfection, and images were obtained under a magnification of 40× for each group. All experiments were performed in triplicate.

Cell Invasion Assays {#S0002-S2006}
--------------------

The invasive ability of transfected cells was determined by transwell assay. Cells were cultured in 100 μL serum-free DMEM after transfection for 48 h. Transwell insert chamber coated with Matrigel (BD Biosciences, San Jose, CA, USA) was used according to manufacturer's instruction. By contrast, the migrated cells on the bottom side were fixed with 4% polyoxymethylene and stained with 0.1% crystal violet for 20 min at 4°C. The invading cells at 100× magnification were counted using the Adobe Photoshop CS5. All experiments were performed in triplicate.

Western Blot Assays {#S0002-S2007}
-------------------

Total cell lysates were prepared with sample buffer and boiled at 95°C for five minutes. Protein samples were transferred to 10% polyacrylamide gel electrophoresis (SDS-PAGE) for three hours, and then the samples were moved to polyvinylidene fluoride (PVDF). After incubation with primary antibodies (1:10,000) for *ADAMTS9*, *AKT*, p-AKT1, *PIK3CB*, mTOR, p-mTOR, LC3, *BECN1*, *SQSTM1*, Bax and Bcl-2 at 4°C overnight. All these antibodies were purchased from ABclonal (China). Peroxidase-conjugated goat anti-mouse (1:10,000) was used as a secondary antibody for *GAPDH* and *BECN1* at 37°C for one hour. Peroxidase-conjugated goat anti-rabbit IgG (1:10,000) were used as a secondary antibody for other proteins at 37°C for one hour. The PVDF membrane was developed using ECL chemiluminescent reagent (EMD Millipore, Billerica, MA, USA). *GAPDH* was used as an internal control. The images were obtained using Bio-Rad Gel Doc XR^+^ system (Bio-Rad Laboratories Inc., Hercules, CA, USA). Each sample was examined in triplicate.

Gene Expression Omnibus (GEO) Data Extraction {#S0002-S2008}
---------------------------------------------

Using GEO database ([<https://www.ncbi.nlm.nih>]{.ul}. gov/geo/), the clinical samples of bladder cancer were obtained. First, the gene expression data sets of bladder cancer and adjacent tissues were processed by R language. Second, the matrix of gene expressions was generated and uploaded to Gene Set Enrichment Analysis (GSEA) platform ([<http://software.broadinstitute.org/gsea/index.jsp>]{.ul}) for enrichment analysis. Further, the expression profiles, pathway enrichment and the gene enrichment maps were obtained, separately. Finally, the correlation coefficient map between of *ADAMTS9-AS2* and *ADAMTS9* was calculated by Cor function in the R-language.

Statistical Analysis {#S0002-S2009}
--------------------

All data were analyzed with GraphPad Prism 7.0 software (GraphPad Software Inc., La Jolla, CA, USA) and the data were expressed as mean ±SD. Student's *t*-test was used to analyze differences between two groups. All experiments were performed in triplicate. *P* \<0.05 was considered to indicate a statistically significant difference.

Results {#S0003}
=======

Downregulation of *ADAMTS9-AS2* in Bladder Tumor Cells {#S0003-S2001}
------------------------------------------------------

*ADAMTS9-AS2* expression was determined in one normal cell line SV-HUC-1 and five bladder tumor cell lines (UC3, 5637, J82, T24, and EJ) using qRCR. Compared to the normal cell line SV-HUC-1, *ADAMTS9-AS2* expression was downregulated in UC3, 5637, J82, T24, and EJ cells, apparently in UC3 and 5637 ([Figure 1](#F0001){ref-type="fig"}, *P* \<0.001). Thus, bladder tumor cell lines UC3 and 5637 were chosen for the functional experiments. Besides, the *ADAMTS9* expression was also identified using qRCR. It suggested that *ADAMTS9* was downregulated in UC3, 5637, J82, T24, and EJ cell lines ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=245826.docx)]{.ul}). The results suggested that *ADAMTS9-AS2* and *ADAMTS9* were downregulated in bladder tumor cells.Figure 1Downregulation of *ADAMTS9-AS2* in bladder tumor cells.**Notes:** Based on the qPCR assays, *ADAMTS9-AS2* expression in bladder tumor lines was determined in one normal cell line SV-HUC-1 and five bladder tumor cell lines (UC3, 5637, J82, T24, and EJ). Compared to the normal cell line SV-HUC-1, the expression of *ADAMTS9-AS2* was downregulated in UC3, 5637, J82, T24, and EJ cell lines, apparently in UC3 and 5637 cells. \**P* \<0.01; \*\**P* \<0.001.**Abbreviations:** q-PCR, quantitative PCR 12 13.

*ADAMTS9-AS2* was Positively Related to *ADAMTS9* in 5637 and UC3 Cells {#S0003-S2002}
-----------------------------------------------------------------------

Using the GEO database, a weak positive correlation with 0.42 has been observed between *ADAMTS9-AS2* and *ADAMTS9* ([[Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=245826.docx)]{.ul}). Importantly, to pinpoint the relationship between *ADAMTS9-AS2* and *ADAMTS9*, *ADAMTS9-AS2* knockdown and overexpression experiments were conducted separately. *ADAMTS9-AS2* overexpression experiments were conducted in the first place. After pcDNA3.1 control and pcDNA3.1-AS2 were transfected into 5637 and UC3 cell lines, respectively, *ADAMTS9-AS2* expression was rising in parallel with increasing *ADAMTS9* expression ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}; *P* \<0.01). For *ADAMTS9-AS2* knockdown experiments, si-NC, si-AS2-1 and si-AS2-2 were transfected into 5637 and UC3 cell lines, respectively, which showed that downregulated *ADAMTS9-AS2* resulted in the reduction of *ADAMTS9* expression and no significant changes in UC3 cells transfected with si-AS2-1 group ([Figure 2C](#F0002){ref-type="fig"} and [D](#F0002){ref-type="fig"}; *P* \<0.05). The results suggested that *ADAMTS9-AS2* was positively related to *ADAMTS9* in bladder tumor cells.Figure 2*ADAMTS9-AS2* was positively related to *ADAMTS9* in 5637 and UC3 cells.**Notes:** (**A, B**) *ADAMTS9-AS2* overexpression experiments were first conducted. pcDNA3.1 control and pcDNA3.1-AS2 were transfected into 5637 and UC3 cell lines, respectively. It suggested that *ADAMTS9-AS2* expression was rising in parallel with increasing *ADAMTS9* expression. (**C, D**) For *ADAMTS9-AS2* knockdown experiments, si-NC, si-AS2-1 and si-AS2-2 were transfected into 5637 and UC3 cell lines, correspondingly, which showed that downregulated *ADAMTS9-AS2* resulted in the reduction of *ADAMTS9* expression and only no significant changes in UC3 cells transfected with si-AS2-1 group. \**P* \<0.05; \*\**P* \<0.01; \*\*\**P* \<0.001.**Abbreviations:** siRNA, small interfering RNA; ns, no significance; NC, negative control.

*ADAMTS9-AS2* Inhibits the Proliferation Ability of 5637 and UC3 Cells {#S0003-S2003}
----------------------------------------------------------------------

To further explore the effect of *ADAMTS9-AS2* on proliferation ability, *ADAMTS9-AS2* overexpression and knockdown experiments in 5637 and UC3 cell lines were performed. The CCK8 and clonogenic assays demonstrated that in cells transfected with pcDNA3.1-AS2 group, the proliferation ability was curbed compared with those transfected with pcDNA3.1 control group ([Figure 3A](#F0003){ref-type="fig"}--[D](#F0003){ref-type="fig"}; *P* \<0.05), while it was promoted in cells transfected with si-AS2-2 as compared to si-NC group ([Figure 3A](#F0003){ref-type="fig"}--[D](#F0003){ref-type="fig"}; *P* \<0.05). The results suggested that *ADAMTS9-AS2* inhibits the proliferation ability of bladder tumor cells.Figure 3*ADAMTS9-AS2* inhibits the proliferation ability of 5637 and UC3 cells.**Notes:** (**A** and **C**) In 5637 cells, CCK8 assays and clonogenic assays demonstrated that cells in transfected with the pcDNA 3.1-AS2 group, the proliferation ability was curbed compared with those transfected with pcDNA3.1 control, while it was promoted in cells transfected with si-AS2-2 as compared to si-NC group. (**B** and **D**) In UC3 cells, similar results obtained from CCK8 and clonogenic assays, the proliferation ability was inhibited in the *ADAMTS9-AS2* overexpression group but enhanced in the *ADAMTS9-AS2* knockdown group. \**P* \<0.05; \*\**P* \<0.01; \*\*\**P* \<0.001**Abbreviations:** siRNA, small interfering RNA; NC, negative control.

*ADAMTS9-AS2* Suppresses the Migration Ability of 5637 and UC3 Cells {#S0003-S2004}
--------------------------------------------------------------------

The scratch wound healing assays showed that the migration ability in 5637 and UC3 cells transfected with the pcDNA 3.1-AS2 group was restrained in comparison with those in pcDNA 3.1 group ([Figure 4A](#F0004){ref-type="fig"}--[D](#F0004){ref-type="fig"}). On the flip side, cells were transfected with si-NC or si-AS2-2 to further confirm the influence of *ADAMTS9-AS2*, which showed that cell migration ability in the si-AS2-2 group was strengthened compared to si-NC ([Figure 4A](#F0004){ref-type="fig"}--[D](#F0004){ref-type="fig"}). Concisely, *ADAMTS9-AS2* suppresses the migration ability of bladder tumor cells.Figure 4*ADAMTS9-AS2* suppresses the migration ability of 5637 and UC3 cells.**Notes:** (**A** and **C**) In 5637 cells, transwell assays found that invasion ability of cells transfected with the pcDNA 3.1-AS2 group had abated compared to the corresponding pcDNA 3.1 control group, while cell invasion ability in si-AS2-2 groups was enhanced compared to their corresponding si-NC group. (**B** and **D**) In UC3 cells, *ADAMTS9-AS2* overexpression also restrained the migration ability, and its knockdown promoted the migration ability of cells. \**P* \<0.05**Abbreviations:** siRNA, small interfering RNA; NC, negative control.

*ADAMTS9-AS2* Restrains the Invasion Ability of 5637 and UC3 Cells {#S0003-S2005}
------------------------------------------------------------------

The transwell assays found that the invasion ability of 5637 and UC3 in cells transfected with the pcDNA 3.1-AS2 group had abated compared to the corresponding NC group ([Figure 5A](#F0005){ref-type="fig"}--[D](#F0005){ref-type="fig"}; *P* \<0.01). Cells were transfected with si-NC or si-AS2-2 to further identify the roles of *ADAMTS9-AS2*. The knockdown experiments in 5637 and UC3 cell lines suggested that cell invasion ability in si-AS2-2 groups were enhanced compared to their corresponding si-NC group ([Figure 5A](#F0005){ref-type="fig"}--[D](#F0005){ref-type="fig"}; *P* \<0.01). Collectively, these findings suggested that *ADAMTS9-AS2* inhibits the proliferation, migration, and invasion ability of bladder tumor cells.Figure 5*ADAMTS9-AS2* restrains the invasion ability of 5637 and UC3 cells.**Notes:** (**A, B**) In 5637 cells, the transwell assay found that the invasion ability of cells transfected with the pcDNA 3.1-AS2 group was inhibited compared to the corresponding NC group, whereas the invasion ability was enhanced in the si-AS2-2 group compared to the si-NC group. (**C, D**) In UC3 cells, similarly, cell invasion ability was inhibited in the *ADAMTS9-AS2* overexpression group, whereas it was enhanced in the *ADAMTS9-AS2* knockdown groupcompared to their corresponding NC group. \**P* \<0.01.**Abbreviations:** siRNA, small interfering RNA; NC, negative control.

*ADAMTS9-AS2* Blocked *PI3K*/*AKT*/mTOR Signal Pathway in 5637 and UC3 Cells {#S0003-S2006}
----------------------------------------------------------------------------

As mentioned earlier, the activation of *PI3K*/*AKT* was closely related to abnormal expression of a large number of lncRNAs.[@CIT0021],[@CIT0027] To investigate the potential mechanism of *ADAMTS9-AS2* in bladder cancer, therefore, the associations between *ADAMTS9-AS2* and *PI3K*/*AKT*/mTOR pathway related markers were analyzed. Western blot assays were first conducted to analyze the expression of p-AKT, *PIK3CB* and p-mTOR at phosphorylation level. *ADAMTS9-AS2* overexpression experiment or knockdown experiment were conducted in 5637 and UC3 cell lines. It showed that the expressions of p-AKT, *PIK3CB* and p-mTOR were inhibited in cells transfected with pcDNA 3.1-AS2 group compared to pcDNA 3.1 group ([Figure 6A](#F0006){ref-type="fig"} and [B](#F0006){ref-type="fig"}). *ADAMTS9-AS2* knockdown experiment suggested that the expression of p-AKT, *PIK3CB* and p-mTOR was enhanced in the si-AS2-2 group compared to si-NC group ([Figure 6A](#F0006){ref-type="fig"} and [B](#F0006){ref-type="fig"}). *ADAMTS9-AS2* overexpression or knockdown had no significant effects on *AKT1* and mTOR ([Figure 6A](#F0006){ref-type="fig"} and [B](#F0005){ref-type="fig"}). These results suggested that *ADAMTS9-AS2* might block the *PI3K*/*AKT*/mTOR signal pathway in bladder cancer cells.Figure 6*ADAMTS9-AS2* blocked *PI3K*/*AKT*/mTOR signal pathway in 5637 and UC3 cells.**Notes:** (**A**) In 5637 cells, from the results of Western blot assays, the expressions of p-AKT, *PIK3CB*, and p-mTOR were inhibited in cells transfected with the pcDNA 3.1-AS2 group compared to the pcDNA 3.1 group, while p-AKT, *PIK3CB*, and p-mTOR were enhanced in the si-AS2-2 group compared to si-NC group. *ADAMTS9-AS2* overexpression or knockdown had no significant effects on *AKT1* and mTOR. (**B**) In UC3 cells, similarly, Western blot assays also indicated that p-AKT, *PIK3CB*, and p-mTOR were restrained in the *ADAMTS9-AS2* overexpression group, whereas their expressions were enhanced in the *ADAMTS9-AS2* knockdown group.**Abbreviations:** siRNA, small interfering RNA; NC, negative control.

*ADAMTS9-AS2* was Essential to Autophagy and Apoptosis in 5637 and UC3 Cells {#S0003-S2007}
----------------------------------------------------------------------------

The *PI3K*/*AKT*/mTOR pathway has been widely explored to reflect the apoptosis process.[@CIT0028],[@CIT0030] In fact, the mechanistic target of rapamycin (mTOR) serves as a central controller of cell growth signaling to autophagy.[@CIT0031] To further reveal the functional roles of *ADAMTS9-AS2*, its effect on autophagy and apoptosis was investigated. Similarly, *ADAMTS9-AS2* overexpression and knockdown experiments were conducted in 5637 and UC3 cell lines. Expressions of several key autophagy (LC3-I, LC3-II, *BECN1*, and *SQSTM1*) and apoptotic proteins (Bax and Bcl-2) were observed by Western blot assays.

For *ADAMTS9-AS2* overexpression experiment, cells were transfected with pcDNA 3.1 or pcDNA 3.1-AS2. We found that *ADAMTS9*, LC3-II, *BECN1*, and proapoptotic Bax expression were increased, but *SQSTM1* and antiapoptotic Bcl-2 expression were decreased in pcDNA 3.1-AS2 group compared to their corresponding pcDNA 3.1 group ([Figure 7A](#F0007){ref-type="fig"} and [B](#F0007){ref-type="fig"}). For the *ADAMTS9-AS2* knockdown experiment, we noticed that *ADAMTS9*, LC3-II, *BECN1*, and proapoptotic Bax expression were reduced in cells transfected with si-AS2-2 group compared with si-NC, while *SQSTM1* and antiapoptotic Bcl-2 expression were elevated in si-AS2-2 group compared to si-NC group ([Figure 7A](#F0007){ref-type="fig"} and [B](#F0007){ref-type="fig"}). We did not detect obvious impact on LC3-I in *ADAMTS9-AS2* overexpression or knockdown experiment ([Figure 7A](#F0007){ref-type="fig"} and [B](#F0007){ref-type="fig"}). All these results indicate a potential regulatory mechanism of *ADAMTS9-AS2* involved in autophagy and apoptosis in bladder tumor cells.Figure 7*ADAMTS9-AS2* was essential to autophagy and apoptosis in 5637 and UC3 cells.**Notes:** (**A**) In 5637 cells, from the results of Western blot assays, *ADAMTS9*, LC3-II, *BECN1*, and proapoptotic Bax expression were increased in pcDNA 3.1-AS2 group, but reduced in cells transfected with si-AS2-2 group compared with corresponding NC group. In addition, *SQSTM1* and antiapoptotic Bcl-2 expression were decreased in the pcDNA 3.1-AS2 group, whereas they were elevated in the si-AS2-2 group compared to the NC group. (**B**) In UC3 cells, similar results were obtained from Western blot assays. *ADAMTS9*, LC3-II, *BECN1*, and proapoptotic Bax expressions were rising in the *ADAMTS9-AS2* overexpression group, while they were reduced in the *ADAMTS9-AS2* knockdown group; *SQSTM1* and antiapoptotic Bcl-2 expressions were decreased as *ADAMTS9-AS2* overexpression, while they were abated as *ADAMTS9-AS2* knockdown.**Abbreviations:** siRNA, small interfering RNA; NC, negative control.

Discussion {#S0004}
==========

It has been well-recognized that a host of lncRNAs were closely related to the pathogenesis of bladder cancer.[@CIT0032] Nevertheless, the roles of *ADAMTS9-AS2* in the bladder tumor remain largely unknown. It is well known that *ADAMTS9-AS2* is an antisense transcript of *ADAMTS9*.[@CIT0011],[@CIT0033] A growing number of research has shown that a pair of sense and antisense transcripts commonly plays a pivotal role in the tumors, like *SPINT1-AS1* and *SPINT1* in colorectal cancer,[@CIT0034] *FOXF1-AS1* and *FOXF1* in osteosarcoma cells;[@CIT0035] *AFAP1-AS1* and *AFAP1* in breast cancer;[@CIT0036] *MAPT-AS1* and *MAPT* in breast cancer.[@CIT0037] From the GEO analysis results, red represents positive correlation, which indicated that *ADAMTS9-AS2* and *ADAMTS9* had a weak positive correlation. Therefore, the potential association of *ADAMTS9-AS2* and *ADAMTS9* gave rise to the insights into the investigation of bladder cancer. Using the qPCR assays, *ADAMTS9-AS2* expressions in one normal cell line SV-HUC-1 and five bladder cancer cell lines (UC3, 5637, J82, T24, and EJ) were first identified. Because *ADAMTS9-AS2* was apparently downregulated in the 5637 and UC3 cell lines, the two cell lines were applied in following assays. From the *ADAMTS9-AS2* overexpression and knockdown experiments, the association between *ADAMTS9-AS2* and *ADAMTS9* were identified. We found that *ADAMTS9-AS2* was positively related to *ADAMTS9* in 5637 and UC3 cells, which is in line with the previous study.[@CIT0038] Albeit the diverse roles of *ADAMTS9-AS2* has been reported in a variety of tumors,[@CIT0015],[@CIT0017] it still remains largely unclear whether *ADAMTS9-AS2* could bring out the effects on bladder tumor cells. To identify the functional roles of *ADAMTS9-AS2* in bladder tumor cells, CCK8, clonogenic assay, scratch wound healing, and transwell assay were performed, respectively. We found that *ADAMTS9-AS2* overexpression inhibits the proliferation, migration, and invasion ability in bladder cancer lines 5637 and UC3. Conversely, its knockdown had positive results. Given the information from GEO database and several pairs of sense and antisense related studies,[@CIT0034],[@CIT0037] we speculated that *ADAMTS9-AS2* might play a role in bladder tumor by regulating the *ADAMTS9* expression. Besides, *ADAMTS9* functions as a critical player in the process of *AKT*/mTOR signaling pathway as evidenced by Chen et al.[@CIT0033],[@CIT0039] Noticeably, the activation of the *PI3K*/*AKT*/mTOR signaling pathway is widely recognized as an essential part of regulatory mechanism in tumors including bladder cancer.[@CIT0040],[@CIT0042] As previously mentioned, *ADAMTS9-AS2* expression was correspondent with *ADAMTS9*. We thus proceeded with deep investigation concerning the association of *ADAMTS9-AS2* and *PI3K*/Akt/mTOR pathway related markers. Results based on Western blot assays indicated that *ADAMTS9-AS2* inhibited p-AKT, *PIK3CB*, and p-mTOR. Previous study noticed that *PI3K*/Akt/mTOR was closely related to autophagy and apoptosis.[@CIT0031],[@CIT0043] The autophagy related several key markers (LC3-I, LC3-II, *BECN1*, and *SQSTM1*) and apoptotic proteins (Bax and Bcl-2) were further explored. It suggested that *ADAMTS9-AS2* promoted LC3-II, *BECN1*, and proapoptotic Bax, but inhibited *SQSTM1* and antiapoptotic Bcl-2 expression. The data we present might highlight the biological functions of *ADAMTS9-AS2* in bladder tumor. In addition, we further explored the reasonable mechanism that *ADAMTS9-AS2* inhibited the proliferation, migration, and invasion via *PI3K*/Akt/mTOR signaling pathway. Nevertheless, our study exists some limitations, such as, functional experiments were performed only in two cell lines; the precise molecular mechanism underlying the *ADAMTS9-AS2* and *ADAMTS9* require further investigation. Therefore, further studies will be considered to reveal the specific mechanisms of *ADAMTS9-AS2* in bladder tumor.

Conclusion {#S0005}
==========

Our results found the functional roles and potential mechanisms of *ADAMTS9-AS2* in bladder tumor. It suggested that *ADAMTS9-AS2* could inhibit cell proliferation, migration, and invasion ability in bladder tumor. Our work might provide valuable insights into a possible mechanism that *ADAMTS9-AS2* is a tumor suppressor involved in the *PI3K*/*AKT*/mTOR signal pathway causing cell autophagy and apoptosis in bladder tumor.
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